Sotera Health

SHC

市值 US$51.1億

Sotera Health Company is rated BUY, leveraging a vertically integrated model and strong MOAT in global medical equipment sterilization. SHC benefits from high customer switching costs, multi-year contracts with major healthcare firms, and robust pricing power in mission critical services. Q2 2026 results exceeded expectations, prompting raised full-year guidance; SHC trades at a discount to peers on forward EV/EBITDA despite superior margins.

Sotera Health Company (SHC) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Sotera Health NASDAQ: SHC reported second-quarter 2026 results that included 8% constant-currency revenue growth, higher adjusted EBITDA margins and an increase to its full-year revenue and adjusted EBITDA outlook.

Sotera Health Company (SHC) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Sotera Health Company (SHC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.2 per share a year ago.

Q2 2026 net revenues increased 9.2% or 8.0% on a constant currency basis (1) compared to Q2 2025 Q2 2026 net income of $54 million or $0.19 per diluted share, compared to net income of $8 million or $0.03 per diluted share in Q2 2025 Q2 2026 Adjusted EBITDA ( 1 ) increased 10.0%, or 8.7% on a constant currency basis Q2 2026 Adjusted EPS (1) of $0.26, an increase of 30% per diluted share Company raises both full-year 2026 net revenues growth out look to 5.25% - 6.75% and Adjusted EBITDA growth outlook to 5.75% - 7.25%, on a constant currency basis CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the three- and six- months ended June 30, 2026. “We delivered another strong quarter, with high-single-digit growth, reflecting focused execution across all three of our business units,” said Chief Executive Officer Alton Shader.

CLEVELAND, July 23, 2026 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the second-quarter ended June 30, 2026 before the market opens on Thursday, August 6, 2026. Following the release, management will host a conference call at 9:00 a.m.

Sotera Health Company (SHC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Sotera Health Company (SHC) Presents at Jefferies Global Healthcare Conference 2026 Transcript